French drugmaker Sanofi said on Thursday it was “surprised” by a renewed, higher offer for its consumer arm Opella from private equity firm PAI Partners, saying the move came after the bidding deadline for the business had passed. PAI is seeking to outbid U.S. rival Clayton Dubilier & Rice (CD&R) for a controlling 50% stake in Opella, the maker of one of France’s most-sold painkillers, Doliprane, a source earlier told Reuters, confirming media reports.
Read the full article: Sanofi ‘Surprised’ by PAI Partners’ Raised Bid for Opella Unit //
Source: https://www.reuters.com/markets/deals/pai-partners-makes-higher-offer-sanofis-opella-says-le-monde-2024-10-17/